NeuroSense Therapeutics Ltd. announced the expansion of its board of directors with the appointment of four new directors upon the closing of the company's recent IPO. The new directors will join the current directors, Mark Leuchten berger, Chairman of the Board, and Alon Ben-Noon, the CEO and founder. The new directors bring a diverse set of experiences in healthcare and the biotechnology industry that will be instrumental for guiding NeuroSense through the development and commercialization of its product portfolio. Joining the NeuroSense board are: Yael German, a former Israeli Member of Knesset and former Minister of Health; Caren Deardorf, currently Chief Commercial Officer at Magenta Therapeutics, who previously led multiple global launches across rare disease and neurology at Biogen Inc.; Christine Pellizzari, currently Chief Legal Officer at Science 37 and a veteran of several rare disease focused biotech companies in similar roles; and Cary Claiborne, currently Chief Operating Officer and board member at Adial Pharmaceuticals and the founder and CEO of Prosperity Capital Management, LLC. Ms. Pellizzari will chair the Compensation Committee and Mr. Claiborne, with extensive experience as the CFO of several biotech companies, will chair the Audit Committee.